美国食品药品监督管理局（FDA）已批准Tryngolza®（奥莱扎森）上市，该药物成为首个且唯一获批用于降低严重高甘油三酯血症患者甘油三酯水平及急性胰腺炎风险的疗法。
美国食品药品监督管理局（FDA）已批准Tryngolza®（奥莱扎森）上市，该药物成为首个且唯一获批用于降低严重高甘油三酯血症患者甘油三酯水平及急性胰腺炎风险的疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.